Balyasny Asset Management
NMRA icon

Balyasny Asset Management’s Neumora Therapeutics NMRA Stock Holding History

Balyasny Asset Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
+57,642
New +$149K ﹤0.01% 2749
2024
Q3 		– Sell
-380,160
Closed -$3.74M – 3021
2024
Q2 		$3.74M Sell
380,160
-308,009
-45% -$3.19M 0.01% 1303
2024
Q1 		$9.46M Buy
+688,169
New +$11.1M 0.02% 954

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Balyasny Asset Management's NMRA Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Neumora Therapeutics (NMRA) in Q1 2026: 57,642 shares worth $112K. The stake represents ﹤0.01% of the portfolio and ranks #2749 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in NMRA as recently as Q2 2024.

Balyasny Asset Management first reported a position in NMRA in Q1 2024 and has held it in 3 quarters since. The position peaked at $9.46M in Q1 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Balyasny Asset Management held 57,642 shares of Neumora Therapeutics worth $112K as of Q1 2026.
  • Neumora Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Neumora Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2749 holding.
  • Balyasny Asset Management first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Balyasny Asset Management's Neumora Therapeutics position peaked at $9.46M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.